DMTF1 and breast carcinoma: The same trend was also found in breast cancer samples in WFUHS [42] since none of the 10 patients that showed dual LOH for p53 and hDMP1 relapsed during the 2100 days of observation period (p = 0.0189, χ2 = 7.9382, n = 105) (Figure 2C).